slides · global inventory
Solution
Slide type collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 8,880
Current window 5,101-5,130
Pages 296
Rows per page 30
Slide type
5,101-5,130 of 8,880
14
The slide uses a process flow diagram to show the integration of clinical inputs, payer tools, and care management.Apollo Medical Holdings | Investor Presentation Deck | 45 slides · Apollo Medical Holdings
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
15
The slide uses a process flow diagram to show data integration and workflow automation.Apollo Medical Holdings | Investor Presentation Deck | 45 slides · Apollo Medical Holdings
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
16
The slide uses a process flow diagram to show the integration of payer tools into the provider-patient care loop.Apollo Medical Holdings | Investor Presentation Deck | 45 slides · Apollo Medical Holdings
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
17
The slide uses a hub-and-spoke style diagram to show data flow from clinical inputs into the central engine.Apollo Medical Holdings | Investor Presentation Deck | 45 slides · Apollo Medical Holdings
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
05
The slide uses a hierarchical structure to connect a high-level objective to three distinct operational pillars.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations Beat · Solution1 hit
07
The slide uses a hub-and-spoke diagram to represent the platform model.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
21
The slide uses a vertical timeline/process flow to show the progression of clinical development alongside key de-risking milestones.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
07
The slide uses a hub-and-spoke diagram to illustrate data integration and a 2x2 matrix to represent the platform's core capabilities.BenevolentAI | Investor Presentation Deck | 46 slides · BenevolentAI
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
08
The slide uses a comparative framework to contrast industry standards with AI-enhanced outcomes across two distinct R&D phases.BenevolentAI | Investor Presentation Deck | 46 slides · BenevolentAI
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
09
The slide uses a process flow diagram to illustrate the transformation of raw data into actionable scientific insights.BenevolentAI | Investor Presentation Deck | 46 slides · BenevolentAI
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
22
The slide uses a process diagram to explain the experimental setup (biopsy -> organ culture -> measurement) followed by bar charts showing efficacy.BenevolentAI | Investor Presentation Deck | 46 slides · BenevolentAI
Pitch deck Investor relations 1 hit
33
Uses a 2x2 matrix to represent the platform components.BenevolentAI | Investor Presentation Deck | 46 slides · BenevolentAI
Pitch deck Investor relations 1 hit
34
The slide uses a process flow diagram to illustrate data ingestion, NLP-based extraction, and the resulting knowledge graph.BenevolentAI | Investor Presentation Deck | 46 slides · BenevolentAI
Pitch deck Investor relations 1 hit
36
The slide uses a process flow framework to detail the specific steps in the Target ID phase, including TPA (Target Progressibility Assessment).BenevolentAI | Investor Presentation Deck | 46 slides · BenevolentAI
Pitch deck Investor relations 1 hit
37
The slide uses a vertical timeline on the left to anchor the four steps: Tech Approach, Predict, Triage, and Assay.BenevolentAI | Investor Presentation Deck | 46 slides · BenevolentAI
Pitch deck Investor relations 1 hit
38
The central circular diagram represents a feedback loop between lab capabilities and data integration.BenevolentAI | Investor Presentation Deck | 46 slides · BenevolentAI
Pitch deck Investor relations 1 hit
41
Includes multiple charts showing inhibition of cytokines and reduction of inflammation.BenevolentAI | Investor Presentation Deck | 46 slides · BenevolentAI
Pitch deck Investor relations 1 hit
42
The diagram uses a process flow to show where BEN-2293 fits into the treatment landscape relative to existing therapies.BenevolentAI | Investor Presentation Deck | 46 slides · BenevolentAI
Pitch deck Investor relations 1 hit
45
The slide uses a causal chain framework to link PDE10 inhibition to therapeutic outcomes.BenevolentAI | Investor Presentation Deck | 46 slides · BenevolentAI
Pitch deck Investor relations 1 hit
21
Bionomics | Investor Presentation Deck | 59 slidesBionomics | Investor Presentation Deck | 59 slides · Bionomics
Pitch deck Investor relations Beat · Solution1 hit
24
The slide uses a circular crop for the image, which is a common design element in pitch decks to create visual interest.Bionomics | Investor Presentation Deck | 59 slides · Bionomics
Pitch deck Investor relations Beat · Solution1 hit
42
Includes a detailed biological process diagram and a conceptual model of disease state vs. normalized state.Bionomics | Investor Presentation Deck | 59 slides · Bionomics
Pitch deck Investor relations 1 hit
46
The slide uses a pharmacokinetic line chart to demonstrate rapid absorption and a bulleted list to summarize clinical efficacy in GAD and panic models.Bionomics | Investor Presentation Deck | 59 slides · Bionomics
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
57
The slide uses a list-based framework to highlight five key pillars of the drug's value proposition.Bionomics | Investor Presentation Deck | 59 slides · Bionomics
Pitch deck Investor relations 1 hit
05
The slide uses a comparative structure to explain two different CAR-T approaches.Cabaletta Bio | Investor Presentation Deck | 23 slides · Cabaletta Bio
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
11
The slide compares the CABA-201 construct components to established academic benchmarks and highlights clinical validation of the underlying binder technology.Cabaletta Bio | Investor Presentation Deck | 23 slides · Cabaletta Bio
Pitch deck Investor relations 1 hit
26
The slide uses a comparison framework to map user needs to product capabilities.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations Beat · Solution1 hit
30
The slide highlights the lack of existing FDA-approved therapies for FSAD.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
33
The slide uses a bulleted list to define the product profile and concludes with a strong market gap statement regarding FSAD.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
40
The slide uses a side-by-side comparison structure to link the biological rationale with the technical solution.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit